Audit: QRS - B. pseudocatenulatum for Health & Longevity

Audit conducted on 27/08/2026 20:05 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	85
Failed	0
N/A	8
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Every cell traced to ER: protocol cells to ER Therapeutic Protocol, time cells to Practical Considerations and Therapeutic Protocol, benefits/risks to the ER tier headings, monitoring rows to the ER biomarker table, qualitative items to the ER qualitative list.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	“No consensus dose exists”, “no circadian advantage tested”, “No established target” all carried through from the ER.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Pregnancy and breastfeeding remain in the Contraindications gate; the absolute immunosuppressant contraindication stays a stop item and is not demoted to Key Interactions.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Contraindications come only from the ER “Populations who should avoid” list plus the ER’s own “Absolute contraindication” bullet; no Benefit- or Risk-Modifying Factor is surfaced as a gate item.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, NCT identifiers, expert names, or brand names appear. The single strain designation “CECT 7765” appears in the ER for the same dosing fact.
1.6	The QRS does not introduce new attributions.	🟢	No attributions of any kind in the QRS.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	The deflationary framing (“Evidence for taking it is thin”) mirrors the ER Conclusion’s own register.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Numeric targets, dose ranges, and time windows are given without hedging into advice; the sheet gives the reader everything needed to act or decline.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Statements are descriptive throughout (“Food buffers acid and improves survival to the colon”), never imperative.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No directives; gates are stated as conditions, not instructions.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No recommending verbs anywhere in the variable content.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	Text search confirms no second-person pronouns in the document.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Clinical terms retained are load-bearing decision terms (neutropenia, mucositis, Child-Pugh C) that the gates cannot function without.
2.8	Information is presented in a concise and very compact manner	🟢	Every cell is a fragment or single clause; gate items average under nine words.
2.9	It DOES NOT address the reader directly	🟢	Confirmed by text search — no “you”/”your” in the document.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Functional biomarker targets (hs-CRP below 1.0 mg/L, fasting insulin 2–5 µIU/mL) sit well below conventional cut-offs, addressing the optimizing reader.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Stool shotgun metagenomic tracking and a prebiotic-first route are presented without apology for effort or cost.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	The sheet assumes baseline familiarity with CFU dosing, lipid panels, and metagenomic sequencing.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	At-a-glance names the longevity-relevant distinction directly: a marker of healthy aging is not a proven supplement.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“healthy aging”, “extended healthspan” used; the string “anti-aging” does not appear.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	“colony-forming units” abbreviated to the standard unit CFU; drug and condition names use formal register throughout.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fixed headings, gate headings, tier labels, and column headers match the template byte for byte.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 38 template variable names present; marker_#* expanded to marker_1..8 and qualitative_item# to qualitative_item_1..6 as intended.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	A line-by-line diff of the head and full stylesheet against the template shows the only difference is the page_title fill; the three <span website="..."> hooks and the footer disclaimer are unchanged.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section is empty; the unpopulated benefit and risk tiers are governed by items 12.5 and 13.5 instead.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	“Established dose”, “Best time of day”, “Competing approach — prebiotic first”, “Persistence rather than half-life” are the ER’s bold labels verbatim; all eight marker names are verbatim from the ER biomarker table.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	The two time-cell labels the ER supplies no bold label for (“Inflammatory and lipid markers”, “Stool bifidobacterial counts”) are lifted from the ER’s own sentences in Practical Considerations, not invented.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	Text search returns no emoji; the ER’s “⚠️ Conflicted” marker on the tumor-tissue risk is correctly dropped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Thirteen speculative benefits condensed to one line by pairing related items (“liver injury and joint damage”, “mineral and isoflavone availability”); gate items and monitoring “Why” cells reduced to fragments.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14, immediately after the doctype and before the template comment on line 16.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening “—” at line 3, closing at line 13.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; no element repeats the values.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:04" is quoted, correctly so because it contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: b_pseudocatenulatum_2026-0827-1626_Opus_ER.md, matching the ER on disk.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0827-1922, correct format.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” — single word, no version.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” — nickname plus version, no context-window or other qualifier appended.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9 matches the file’s actual name on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys; no stray whitespace or unnecessary quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	“B. pseudocatenulatum for Health & Longevity - Quick Reference Sheet”; ampersand correctly entity-encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	“B. pseudocatenulatum for Health & Longevity”, matching ER canonical_topic.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	08/27/2026, correctly derived from qrs_creation_date 2026-0827-1922.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	“Opus 5”, matching the frontmatter value.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header is the template subline only; the ER’s “Also known as” line is correctly not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Compresses all three Conclusion paragraphs into the decision the reader faces: thin evidence, unremarkable safety, marker ≠ supplement.
7.2	[at_a_glance] is no longer than 60 words	🟢	Exactly 60 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Fiber fermentation and old-age enrichment from Conclusion ¶1; the children’s trial and animal/survey remainder from ¶2; “Safety looks unremarkable” from ¶2; the marker-versus-supplement gap from ¶3.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; “gut bacterium”, “plant fiber”, “inflammation and cholesterol markers” are all lay terms.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	“one small trial in children” carries no author, year, or sample size.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	Direction only (“nudged”); no numbers of any kind.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All eight items trace to that section: seven from the “Populations who should avoid” list, one from the “Absolute contraindication” immunosuppressant bullet.
8.2	[stop_items] represent the Contraindications from the ER	🟢	Complete coverage — all seven ER avoid-population bullets plus the absolute contraindication are represented, with none added.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Eight <li> elements inside the stop_items span.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	ER trailing rationale correctly stripped: “the setting of the published bacteremic pneumonia case” and “on absence of data rather than evidence of harm” both removed. No dash-trailing clauses remain.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Neutrophil threshold (below 500 cells/µL), Child-Pugh C staging, the 30-day surgical window, and named immunosuppressants all preserved.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses anywhere in Key Interactions & Contraindications.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER identifies seven such populations plus an absolute contraindication, and the section is correctly populated rather than left empty.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not left empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All ten items trace to the ER’s interaction bullets in that section.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	The ER lists eleven interaction bullets; the immunosuppressant/chemotherapy bullet is correctly excluded here because it is carried as a stop item, leaving exactly ten.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Ten <li> elements inside the caution_items span.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Every ER “Caution — … Mitigation: …” and “Monitor — …” trailing clause is stripped; the checkpoint-inhibitor bullet’s embedded melanoma citation is dropped.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Every ER bullet that carried a drug list retains named examples — trimmed to the leading one or two per the one-page budget, none dropped entirely.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in this section.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER identifies ten such interactions, and the section is correctly populated.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not left empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three action cells derive from the ER Therapeutic Protocol bullets.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Dose, administration timing, and the prebiotic-first alternative are the three bullets that change what a reader actually does; the remaining bullets (sex, age, genetics, split dosing) all resolve to “not established” and carry no action.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies at least three distinct actionable aspects, so no set is unused.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine cells populated; the dose range, meal timing, and xylooligosaccharide range are the ER’s own figures, and the availability clause in action_3_sub is supported by the ER Sourcing and Quality section.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Marker change at 13 weeks, stool count shift at 14–28 days, and clearance at 1–2 weeks after stopping are the three temporal figures the ER supplies.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	The 13-week inflammatory/lipid window attaches to the ER’s only Medium-tier benefit and leads; the process measure and the washout figure follow.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	Three distinct time aspects exist in the ER, so no set is unused.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine cells populated with ER figures and their ER rationale; no placeholders.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides an explicit “Time to effect” bullet, so the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	Every listed benefit corresponds to an ER Expected Benefits sub-heading at the matching tier.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present in the benefits card.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	ER heading tails such as “During Synbiotic Supplementation”, “in Community-Dwelling Older Adults”, “Through Secondary Bile Acids”, and “Under Diet-Induced Obesity” are all stripped; no Magnitude figures carried over.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any benefits item.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	benefits_high carries style="display: none" with an HTML comment citing the ER’s “No benefit reaches High”; no empty-state text used.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All four Low and all three Speculative risks correspond to ER sub-headings at the matching tier.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present in the risks card.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	ER heading tails such as “From Bile Salt Hydrolase Activity” and “When Taken After Antibiotics” trimmed to the key fact; the eczema odds ratio and the day-180 figure are not carried over.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any risks item.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	risks_high and risks_medium both carry style="display: none" with HTML comments citing the ER’s “No risk reaches High” and “No risk reaches Medium either”.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	All rows derive from the ER Monitoring Protocol & Defining Success biomarker table.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All eight ER table rows present as marker_1 through marker_8, in ER order, with names verbatim and functional ranges preserved.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	“Baseline, twelve weeks, then six-monthly; repeat stool sequencing only after a change of prebiotic, strain, or antibiotics” condenses the ER’s cadence paragraph accurately.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All six items derive from the ER’s “Qualitative markers worth tracking alongside the laboratory panel” list.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All six ER qualitative markers present in ER order: bowel habit, bloating and flatulence, abdominal discomfort, afternoon energy, cognitive clarity, sleep quality.

Issues 27/08/2026 20:05

Pass rate 100.00%. No issues found.

Issues 27/08/2026 19:53

1. 1.3 — Availability claim overstated: Line 485 (action_3_sub) asserts “as no studied strain is marketed”, whereas the ER’s Sourcing and Quality section says “No single-strain consumer product carrying a studied strain is broadly marketed” and records the ED02 strain as present “in one product now in a company-run trial”.

Fixes 27/08/2026 19:53

1. 1.3 — Availability claim overstated: Changed action_3_sub from “as no studied strain is marketed” to “as no studied strain is broadly marketed”, restoring the ER’s qualifier from Sourcing and Quality.

Issues 27/08/2026 19:50

1. 4.5 — Speculative benefits list uncondensed: The benefits_speculative span (lines 558-567) carries all thirteen ER speculative headings verbatim in a single ~440-character bullet, with no per-section budget applied; combined with three-line sub-cells in every protocol and time-to-effect cell, the sheet overruns the one-A4-page design.

Fixes 27/08/2026 19:50

1. 4.5 — Speculative benefits condensed: Merged the thirteen transcribed ER speculative headings into eleven grouped items (“protection against liver injury and joint damage”, “improved mineral and isoflavone availability”), cutting the bullet from ~440 to ~350 characters.
2. 4.5 — Protocol and time sub-cells trimmed: Shortened the three-line sub-cells to two lines each — “Food buffers gastric acid and improves survival to the colon” to “Food buffers acid and improves survival to the colon”, “the practical route today, as no studied strain is broadly marketed” to “as no studied strain is marketed”, and “Supplemented bifidobacteria are cleared over this period; they rarely establish permanently” to “Cleared over this period; supplemented bifidobacteria rarely establish permanently”.

Issues 27/08/2026 19:37

1. 4.3 — Monitoring row label abbreviated: Line 734 renders the ER’s biomarker label “Complete blood count and comprehensive metabolic panel” (ER line 458) as “Complete blood count and metabolic panel”, dropping “comprehensive” and thereby naming a different standard laboratory panel.
2. 13.4 — Parenthetical kept on risk item: Line 626 preserves “(conflicted)” on the tumor-tissue enrichment item, whereas parenthetical content in the Risks card must be stripped.
3. 12.3 — Study-setting qualifier retained: Line 562 keeps “in mice” in “extended healthspan in mice”, while every sibling speculative item strips its setting (e.g. the ER’s “Blood Glucose Lowering in Diabetic Mice” appears as “blood glucose lowering”).
4. 1.2 — Cautious qualifier dropped: Line 773 shortens the ER’s “the uncontrolled synbiotic pilot” (ER line 464) to “the synbiotic pilot”, losing the ER’s evidence-quality caveat.

Fixes 27/08/2026 19:37

1. 4.3 — Monitoring row label restored: Changed marker_8_name from “Complete blood count and metabolic panel” to the ER’s full label “Complete blood count and comprehensive metabolic panel”.
2. 13.4 — Parenthetical stripped from risk item: Removed “(conflicted)” from the tumor-tissue enrichment entry in risks_low, leaving “tumor tissue enrichment”.
3. 12.3 — Study-setting qualifier removed: Changed “extended healthspan in mice” to “extended healthspan” in benefits_speculative, matching how every sibling item strips its setting.
4. 1.2 — Cautious qualifier restored: Changed qualitative_item_3 from “the synbiotic pilot” back to the ER’s “the uncontrolled synbiotic pilot”.

Issues 27/08/2026 19:29

1. 4.5 — QRS overruns one A4 page: Estimated rendered height is roughly double the ~273 mm usable A4 height; the decision-gate block (~18 wrapped lines in the taller column) and the 8-row Monitoring table plus cadence alone consume the page, with benefits_speculative (13 chained items, ~630 characters), the full parenthetical drug lists across all 10 caution_items, and the 3–4 line action/time sub-texts left uncondensed.
2. 7.4 — Research jargon in At-A-Glance: “everything else is association or animal work” uses “association” as a bare research-register mass noun, and “The gap between marker and supplement remains wide” strands “marker” as a technical classification once the ER’s explanatory context at L495 (“its standing as a marker of healthy aging”) was compressed away.

Fixes 27/08/2026 19:29

1. 7.4 — At-A-Glance research jargon: Replaced “everything else is association or animal work” with “the rest is animal work or a pattern seen in surveys”, and the stranded “The gap between marker and supplement remains wide” with “A sign of healthy aging is not a proven supplement”; the passage remains within the 60-word cap.
2. 4.5 — Key Interactions condensed: Trimmed all ten caution items to a representative parenthetical each, e.g. antibiotics from four named drugs to “(azithromycin, metronidazole)” and prebiotic fibers from four to “(xylooligosaccharides, inulin)”, reducing the caution gate column from roughly eighteen wrapped lines to eleven.
3. 4.5 — Contraindications condensed: Shortened the eight stop items while preserving every threshold and staging qualifier, e.g. “absolute neutrophil count below 500 cells per microliter” to “neutrophil count below 500 cells/µL” and “Child-Pugh Class C” to “Child-Pugh C”.
4. 4.5 — Speculative benefits condensed: Stripped the mechanistic and model tails from the thirteen speculative items, e.g. “Reduced fat deposition through secondary bile acids” to “Reduced fat deposition” and “anti-tumor immune activation by the bacterial sugar coat” to “anti-tumor immune activation”, cutting the item from about 630 to about 400 characters.
5. 4.5 — Low benefits and risk tiers condensed: Trimmed qualifiers from the Low benefits item and both visible risk tiers, e.g. “reduced functional abdominal pain during synbiotic supplementation” to “reduced abdominal pain” and “bile acid pool shifts from bile salt hydrolase activity” to “bile acid pool shifts”.
6. 4.5 — Monitoring table condensed: Shortened the Why cell of markers 1–8 and the Target cell of markers 1, 7 and 8, e.g. “Slow-moving confirmation that any metabolic shift is real, not day-to-day noise” to “Confirms a metabolic shift is real”, reducing the table body from roughly seventeen wrapped lines to ten.
7. 4.5 — Protocol sub-texts condensed: Trimmed the action and time-to-effect sub-lines, e.g. action_3_sub from “no single-strain product carrying a studied strain is broadly marketed” to “no studied strain is broadly marketed”, removing one wrapped line from each of the two protocol grid rows.
8. 4.5 — Cadence and qualitative items condensed: Compressed monitoring_cadence to “Baseline, twelve weeks, then six-monthly; repeat stool sequencing only after a change of prebiotic, strain, or antibiotics.” and trimmed the trailing rationale on all six qualitative items.